FDA Warns of a Potential Drug Interaction with Remdesivir for Treatment of COVID-19

The U.S. Food and Drug Administration (FDA) is warning health care providers about a newly discovered potential drug interaction related to the investigational antiviral drug remdesivir, which has received emergency use authorization for the treatment of hospitalized COVID-19 patients with severe disease.

Previous
Previous

How Many Hemophilia Patients Are There?

Next
Next

Update from Dr. David Clark: What We Know and Don’t Know about COVID-19 at This Point